Highlights Cessatech A/S

Equities

CESSA

DK0061411964

End-of-day quote NORDIC GROWTH MARKET Other stock markets 18:00:00 2024-06-26 EDT			5-day change	1st Jan Change
6.1 ^DKK	-0.65%		+1.67%	-15.98%

06-03	Cessatech A/S Announces Superior Simulated Pain Efficacy in Children Favouring Its Lead Candidate Ct001 Relative to Its Active Comparators	CI
05-27	Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Cessatech A/S Announces Superior Simulated Pain Efficacy in Children Favouring Its Lead Candidate Ct001 Relative to Its Active Comparators	06-03	CI
Cessatech A/S Reports First Patient Dosed in Final Safety Study 0202 of Lead Product Candidate CT001	05-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-29	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-16	CI
Cessatech A/S Announces the Paediatric Committee Agrees to Reduce the Number of Required Children in the Final Clinical Study with CT001 from 300 to 150 Children	23-10-25	CI
Cessatech Announces Last Participant Dosed in Pivotal Trial 0205 with Lead Candidate CT001	23-09-21	CI
Cessatech A/S Announces EMA's Paediatric Committee Agrees to Paediatric Investigational Plan for CT002 for Procedural Sedation	23-09-12	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Cessatech A/S and Ventis Pharma Announce US Partnership for CT001	23-06-27	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-29	CI
Cessatech A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-01	CI
Cessatech A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Cessatech A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
Cessatech Reports Successful Outcome of Pharmacokinetic Trial in Children of Lead Candidate	22-09-23	CI
Cessatech A/S Reports First Patient Dosed in Pivotal Trial of Lead Product Candidate	22-09-05	CI
Cessatech A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Cessatech A/S Announces Pivotal Trial 0205 Has Obtained Regulatory Approval	22-06-30	CI
Cessatech Reports Last Patient Dosed in Pharmacokinetic Trial in Children of Lead Candidate	22-05-16	CI
Cessatech A/S Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cessatech A/S

Equities

CESSA

DK0061411964

Highlights

Filters